摘要
目的为探究微小RNA (miRNA)-214在宫颈癌组织中表达与患者临床病理特征及预后的关系。方法实时荧光定量PCR (RT-PCR)法检测84例宫颈癌组织、10例正常宫颈上皮组织中miR-214的表达情况。分析宫颈癌组织中miR-214的表达与患者临床病理特征的关系,并评估miR-214的表达对患者预后的影响。结果 miR-214在宫颈癌组织中的表达较正常宫颈上皮组织中显著下调(P<0. 05)。宫颈癌组织中,miR-214表达与FIGO分期、淋巴结转移、腺体浸润、脉管浸润相关(均P<0. 05),而与患者年龄、肿瘤组织学分型、肿瘤直径、分化程度、人乳头瘤病毒(HPV)感染无关(均P> 0. 05)。KaplanMeier生存分析结果显示,miR-214高表达组患者的术后生存率和平均生存时间均显著优于miR-214低表达组患者(均P <0. 05)。结论 miR-214在宫颈癌组织中的表达显著下调,miR-214可能参与了宫颈癌的发生与转移过程。
Objective To explore the expression of miR-214 in cervical cancer tissue and the relationship with clinicopathological features and prognosis.Methods Real-time fluorescent quantitative PCR was used to detect the expression levels of miR-214 in 84 cases of cervical cancer tissue and 10 cases of normal cervical tissue.The relationship between the expression of miR-214 in cervical cancer tissue and clinicopathologic characteristics was analyzed.The effect of miR-214 expression on the prognosis of patients was evaluated.Results The expression of miR-214 in cervical cancer tissue decreased significantly compared with normal cervical tissue(P<0.05).In cervical cancer tissue,miR-214 expression was associated with FIGO staging,lymph node metastasis,gland involvement,and intravascular involvement(P<0.05),while miR-214 expression was not associated with age,histological types,tumor size,differentiation degree,human papillomavirus(HPV)infection(P>0.05).Kaplan-Meier survival analysis showed that the postoperative survival rate and average survival time in patients with high expression of miR-214 were statistically significantly lower than those in patients with low expression of miR-214(P<0.05).Conclusion The expression of miR-214 in cervical cancer tissue is significantly down-regulated,miR-214 may be involved in occurrence and metastasis of cervical cancer.
作者
李佳
张秀琼
尤玮
韦汉瑶
LI Jia;ZHANG Xiu-Qiong;YOU Wei;WEI Hanyao(Department of Gynecology and Obstetrics,the Third People's Hospital of Zigong,Zigong,Sichuan 643020,China)
出处
《中国妇幼保健》
CAS
2019年第8期1857-1860,共4页
Maternal and Child Health Care of China
基金
四川省医学会课题项目(Q16039)